M344 Suppresses Histone Deacetylase-Associated Phenotypes and Tumor Growth in Neuroblastoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178494 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Gabrielle L Brumfield und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Neuroblastoma, Histone Deacetylases, Benzamides. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Graduate Studies Office, State of Nebraska through the Pediatric Cancer Research Group,, NIGMS NIH HHS.
Abstract (Originalsprache)
Neuroblastoma (NB) is an aggressive pediatric cancer, with high-risk patients facing a five-year survival rate of ~50%. Standard therapies, including surgery, chemotherapy, radiation, and immunotherapy, are associated with significant long-term toxicities and frequent relapse. Histone deacetylase (HDAC) inhibitors have emerged as promising agents for cancer therapy, given their role in modulating gene expression and tumor phenotypes. This study evaluated M344 [4-(dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)benzamide], an HDAC inhibitor, for its efficacy and mechanisms of action against NB. Analysis of clinical NB Gene Expression Omnibus data revealed advanced-stage tumors exhibit higher HDAC expression relative to early-stage samples. M344 treatment effectively increased histone acetylation, induced G0/G1 cell cycle arrest, and activated caspase-mediated cell death. Relative to vorinostat, an HDAC inhibitor in clinical use for lymphoma and clinical trials for NB, M344 displayed superior cytostatic, cytotoxic, and migration-inhibitory effects. In vivo, metronomic M344 dosing suppressed tumor growth and extended survival. Combination therapy with M344 and topotecan improved topotecan tolerability, while M344 co-administration with cyclophosphamide reduced tumor rebound post-therapy. In total, M344 demonstrated strong therapeutic potential for NB, offering improved tumor suppression, reduced off-target toxicities, and enhanced control of tumor growth post-therapy. These findings support further investigation of HDAC inhibitors, such as M344, for clinical application in NB treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eppley Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Children's Nebraska, Omaha, NE 68114, USA.
ORCID-Profile: Gabrielle L Brumfield, Don W Coulter
Förderung
- Graduate Studies Office
- State of Nebraska through the Pediatric Cancer Research Group,
- NIGMS NIH HHS
- NCI NIH HHS
- American Association of Immunologists
- State of Nebraska through the Pediatric Cancer Research Group
- Eppley Institute, the UNMC Graduate Studies Office, the Fred & Pamela Buffett Cancer Center NCI Cancer Center Support Grant
- NCI Training Navigator Program
Zitieren
APA
Brumfield, G. L., Doty, K. R., Knoche, S. M., Larson, A. C., Gephart, B. D., Coulter, D. W., & Solheim, J. C. (2025). M344 Suppresses Histone Deacetylase-Associated Phenotypes and Tumor Growth in Neuroblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178494
Vancouver
Brumfield GL, Doty KR, Knoche SM, Larson AC, Gephart BD, Coulter DW, et al. M344 Suppresses Histone Deacetylase-Associated Phenotypes and Tumor Growth in Neuroblastoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178494
BibTeX
@article{Brumfield2025,
author = {Brumfield, Gabrielle L and Doty, Kenadie R and Knoche, Shelby M and Larson, Alaina C and Gephart, Benjamin D and Coulter, Don W and Solheim, Joyce C},
title = {M344 Suppresses Histone Deacetylase-Associated Phenotypes and Tumor Growth in Neuroblastoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178494}
}
EUVIMED